|
|
|
|
Poor Sleep Patterns Could Affect Your Health and Contribute to Obesity(1)
/PRNewswire/ -- - World Sleep Day - 19th March 2010 As a committed supporter of World Sleep Day, UCB has joined forces with the World Association of Sleep Medicine (WASM) to raise awareness of the importance of sleep for health, and to encourage those with...
|
|
|
Alcoholism Prevention: Data on alcoholism prevention published by researchers at Stanford University
Today's Medical & Research News Alcoholism Prevention Data on alcoholism prevention published by researchers at Stanford University March 18th, 2010 Printer-Friendly Version City:Stanford State:California Country:United States Alcoholism Prevention...
|
|
|
University Of Chicago And Ataxia Foundation Team Up For Annual Scientific And Patient Meetings
The National Ataxia Foundation (NAF), in conjunction with the University of Chicago program in pathobiology and translational neuroscience, will hold its third annual Ataxia Investigators Meeting March 9-11, 2010, at the Hyatt Regency O'Hare, in...
|
|
|
Benefits of Neupro on sleep and early movement in Parkinsons disease
New data from the RECOVER study presented at the XVIII World Federation of Neurology World Congress on Parkinsons Disease and Related Disorders in Miami Beach, Florida, showed that Neupro (rotigotine) was associated with clinically relevant and...
|
|
|
NAF to hold third annual Ataxia Investigators Meeting in Rosemont
The National Ataxia Foundation (NAF), in conjunction with the University of Chicago program in pathobiology and translational neuroscience, will hold its third annual Ataxia Investigators Meeting March 9-11, 2010, at the Hyatt Regency O'Hare, in...
|
|
|
University of Chicago and Ataxia Foundation team up for annual scientific and patient meetings
The National Ataxia Foundation (NAF), in conjunction with the University of Chicago program in pathobiology and translational neuroscience, will hold its third annual Ataxia Investigators Meeting March 9-11, 2010, at the Hyatt Regency O'Hare, in...
|
|
|
University of Chicago and Ataxia Foundation team up for annual scientific and patient meetings
The National Ataxia Foundation (NAF), in conjunction with the University of Chicago program in pathobiology and translational neuroscience, will hold its third annual Ataxia Investigators Meeting March 9-11, 2010, at the Hyatt Regency O'Hare, in...
|
|
|
Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence
Journal of Anesthesia, 03/04/10 Relevance Score: 80% European Journal of Ophthalmology, 03/04/10 Relevance Score: 80% Clinical Journal of Oncology Nursing, 02/18/10 Relevance Score: 80% Movement Disorders, 02/09/10 Relevance Score: 80% Jour Adoption...
|
|
|
2/23/10 - FDA Approves Once-Daily Mirapex ER For The Treatment Of Early Parkinson??s Disease
Boehringer Ingelheim Pharmaceuticals, Inc.announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER For The Treatment Of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER For The Treatment Of Early Parkinson's Disease
Ridgefield, CT/PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
RIDGEFIELD, Conn., Feb.22 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily...
|
|
|
Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
RIDGEFIELD, Conn., Feb.22 /PRNewswire/ Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment...
|
|
|
MIRAPEX ER Approved for Treatment of Early Parkinson's Disease
Medical Information Clinical Trials FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease...Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER ...
|
|
|
2/22/10 - FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
RIDGEFIELD, Conn., Feb.22 /PRNewswire/ Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
RIDGEFIELD, Conn., Feb.22 /PRNewswire/ -- , today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of...
|
|
|
FDA Approves Once-Daily Mirapex ER for the Treatment of Early Parkinson's Disease
RIDGEFIELD, Conn., Feb.22 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
|
|
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early...
|
